Test of 5- Versus 10-Day Remdesivir Treatment in Immunocompromised Patients With Coronavirus Disease 2019.
Test of 5- Versus 10-Day Remdesivir Treatment in Immunocompromised Patients With Coronavirus Disease 2019.
复制标题
对患有 2019 年冠状病毒病的免疫功能低下患者进行 5 天与 10 天瑞德西韦治疗的测试。
DOI：
10.1093/cid/ciac877
复制
发表时间：
2023
期刊：
影响因子：
--
通讯作者：
Yan,VictoriaC
中科院分区：
文献类型：
--
作者：
Yan,VictoriaC
致编辑-Hogan及其同事的一项研究报告了2例接受Remdesivir治疗的移植受者中严重急性呼吸综合征冠状病毒2（SARS-CoV-2）nsp 12中出现的新生V792 I突变[1]。这些病例补充了越来越多的文献，这些文献记录了接受Remdesivir治疗的免疫功能低下患者中SARS-CoV-2的持续性和再感染[2，3]。nsp 12治疗相关突变的出现值得关注，并应促使重新评估使用该药物治疗该患者人群的现行标准。
TO THE EDITOR—A study by Hogan and colleagues reports the emergence of a de novo V792I mutation in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nsp12 in 2 transplant recipients treated with remdesivir [1]. These cases add to a growing body of literature documenting SARS-CoV-2 persistence and reinfection in immunocompromised patients treated with remdesivir [2, 3]. Emergence of treatment-related mutations in nsp12 is cause for concern and should prompt reevaluation of the current standard for treating this patient population with this drug.